Skip to main content

Advertisement

Table 2 Comparison of patients with DCM treated with atorvastatin with and without AF.

From: Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study

  Patients treated with ATORVASTATIN  
PARAMETER AF Group n = 17 No AF Group n = 27 p
Signs of heart failure
dyspnoea (1)* 9 (53%) 8 (30%) ns
dyspnoea (2)* 5 (29%) 7 (26%) ns
oedema (1) 4 (23.5)% 2 (7.5%) ns
oedema (2) 2 (11.7%) 1 (4%) ns
pulmonary haemostasis (1) 2 (11.7%) 2 (7.5%) ns
pulmonary haemostasis (2) 1 (5.8%) 1 (4%) ns
Markers of inflammation mean ± standard deviation mean ± standard deviation  
TNF-α (1) [pg/ml] 21.54 ± 31.33 20.30 ± 21 0.25
TNF-α (2) [pg/ml] 15.21 ± 20.15 9.56 ± 10.72 0.25
IL-6 (1) [pg/ml] 17.91 ± 17.42 16.32 ± 12.76 0.72
IL-6 (2) [pg/ml] 14.16 ± 13.40 6.74 ± 5.45 0.02
IL-10 (1) [pg/ml] 9.98 ± 9.27 19.51 ± 32 0.28
IL-10 (2) [pg/ml] 13.21 ± 9.53 31.40 ± 68.95 0.74
Heart Failure Assessment    
NT-proBNP (1) [pg/ml] 2002.93 ± 1391.52 1518.87 ± 1732.83 0.14
NT-proBNP (2) [pg/ml] 1530.62 ± 1054.27 1006.76 ± 1195.13 0.04
NYHA class (1) median 2 3 0.35
NYHA class (2) median 2 2 0.87
EF (1) [%] 31.13 ± 7 29.82 ± 7.90 0.62
EF (2) [%] 32 ± 8 32.00 ± 8.44 0.84
6-MWT (1) 419.23 ± 72 376.09 ± 108.54 0.14
6-MWT (2) 466.25 ± 104 441.84 ± 118 0.67
  1. * (1) variables assessed after inclusion, (2) variables assessed after 2 months.
  2. ABBREVIATIONS: TNF-α - tumour necrosis factor-alpha; IL - interleukin, 6-MWT - 6-minute walk test; EF - ejection fraction; NYHA - New York Heart Association; NT-proBNP - N-terminal pro-brain natriuretic peptide.